thumb
July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN240)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

thumb
December 9, 2020

Biogen Files New Drug Application for Aducanumab in Japan

If approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimer’s disease Aducanumab is now under regulatory review in Japan, Europe and the United States CAMBRIDGE, Mass. and TOKYO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Today, Biogen (Nasdaq: BIIB) and Eisai,

thumb
November 27, 2020

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S . , excluding rights to zuranolone in Japan, Taiwan and South Korea Sage

thumb
November 18, 2020

Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application for SB11, a proposed biosimilar

thumb
November 16, 2020

Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership

Biogen earns top scores on areas including access to medicine, talent attraction, innovation management and climate performance and reporting In 2013 Biogen became the 1 st U.S. biotech company to appear on the DJSI World Index 2020 marks the 8 th consecutive year that Biogen was listed among top

thumb
November 3, 2020

Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020

Cambridge, Mass. – November 2, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its prerecorded presentation related to its Alzheimer’s disease investigational therapy, aducanumab, as well as a live, virtual question and answer (Q&A) session at the upcoming CTAD 2020 digital

thumb
November 3, 2020

Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting

In Phase 2 LILAC study, BIIB059 demonstrated a statistically significant reduction in joint disease activity compared to placebo in systemic lupus erythematosus patients Positive results build on previously reported cutaneous lupus erythematosus data and underscore Biogen’s commitment to the lupus

thumb
October 30, 2020

European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease  CAMBRIDGE, Mass. and TOKYO, Oct. 30, 2020 (GLOBE NEWSWIRE) --  Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd.

thumb
October 7, 2020

Biogen to Report Third Quarter 2020 Financial Results October 21, 2020

Cambridge, Mass. — Biogen Inc. (Nasdaq: BIIB) today announced it will report third quarter 2020 financial results Wednesday, October 21, 2020, before the financial markets open.  Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

thumb
October 6, 2020

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for SB11, a proposed biosimilar referencing

thumb
September 22, 2020

Biogen to Webcast Prerecorded Encore Aducanumab Presentation and Live Q&A from AAN 2020 Science Highlights on September 23, 2020

Cambridge, Mass. – September 22, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a prerecorded webcast of its encore presentation related to its Alzheimer’s disease investigational therapy, aducanumab, as well as a live, virtual question and answer (Q&A) session at the upcoming AAN 2020